Zealand Pharma offentliggör prospekt och fastställer det preliminära prisintervallet för en börsintroduktion

​NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, OR JAPAN

3 november 2010

Zealand Pharma A/S offentliggör idag prospektet inför den planerade nyemission och börsintroduktionen på NASDAQ OMX Copenhagen. Prisintervallet är satt till mellan 86 till 120 DKK per aktie. Teckning av aktier kan ske mellan den 9 november och 18 november och första handelsdagen är planerad till den 19 november under symbolen "ZEAL".

Zealand Pharma är ett bioteknikföretag med ambitionen att upptäcka och utveckla innovativa peptidbaserade läkemedel för behandling av metabola sjukdomar som diabetes, fetma samt för hjärt - och kärlsjukdomar.

- Jag är väldigt glad över att vi nu tar nästa steg i utvecklingen av Zealand Pharma. Bolaget har idag en bred forskningsportfölj med en mycket stor potential. Genom börsintroduktionen får vi en finansiell bas som säkrar den fortsatta och planerade tillväxten. En notering är också mycket viktig för oss därför att den ökar kännedomen om Zealand Pharma och vår bransch, säger David Solomon, VD för Zealand Pharma.

Danske Bank A/S och Jefferies International Limited är joint global coordinators och joint bookrunners medan Bryan, Garnier & Co och SEB Enskilda är colead managers.

For further information please contact:

Zealand Pharma A/S
David Solomon, President and Chief Executive Officer
Tel: +45 4328 1200

M:Communications
Mary-Jane Elliott / Emma Thompson / Amber Bielecka
Tel: +44(0) 20 7920 2330

Offering Documents

Three Offering Documents have been prepared: a Prospectus in Danish, a Prospectus in English, and a Prospectus in English intended for the Rule 144A private placement in the United States. Special attention should be given to the risk factors, which are described in the beginning of the Offering Documents. The Offering Documents will be made available to eligible investors at no cost at the registered office of Zealand Pharma A/S, Denmark. The Danish Prospectus can also be obtained upon request from Danske Bank A/S, Corporate Actions, Holmens Kanal 2-12, DK-1092 Copenhagen K, phone +45 70 23 08 34, e-mail prospekter@danskebank.dk or from SEB Enskilda, Bernstoffsgade 50, DK-1577 Copenhagen V, phone +45 33 28 29 00, e-mail prospekt@enskilda.dk. The Prospectus may also, subject to certain restrictions, be downloaded from the Company’s website www.zealandpharma.com.

About Zealand Pharma A/S

Zealand Pharma is a Danish biopharmaceutical company dedicated to the discovery and development of innovative peptide drugs. The Company targets diseases where it believes existing treatments fail to adequately serve the medical needs of patients and the market potential for improved treatments through the use of peptide drugs is high.

Zealand Pharma focuses on three therapeutic areas: metabolic (diabetes and obesity), gastrointestinal and cardiovascular diseases. The Company’s expertise in peptide discovery, optimization and development has resulted in a strong and growing pipeline of novel peptide drug candidates with favourable therapeutic attributes.

Since 1999, Zealand Pharma’s scientists have built a pipeline that includes five compounds in clinical development, four of which have been out licensed, two of these with major pharmaceutical companies (sanofi-aventis and Helsinn Healthcare). All of Zealand Pharma’s compounds emerged from the Company’s own drug discovery.

The Company’s investors include, Sunstone Capital, IDinvest Partners, CDC Innovation, LD Pensions, Dansk Erhvervsinvestering and LSP.

Zealand Pharma A/S is based in Copenhagen. For more information please visit the Company’s web site: www.zealandpharma.com.

Disclaimer: The securities described herein may not be offered or sold in the United States unless they are registered or exempt from registration under the U.S. Securities Act of 1933, as amended (the “Securities Act”) and any United States state securities laws. The securities have not been and will not be registered under the Securities Act or any United States state securities laws, and the Company does not intend to make a public offer of its securities in the United States.

This release and the information contained herein does and shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any jurisdiction.

No public offer of securities will be made outside of Denmark. Any offer of securities that may be deemed to be made pursuant to this communication in any EEA Member State, other than Denmark, that has implemented Directive 2003/71/EC (together with any applicable implementing measures in any Member State, the "Prospectus Directive") is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Directive.

This communication does not constitute an offer to the public in the United Kingdom. No prospectus has been or will be approved in the United Kingdom in respect of the Notes. The distribution of this press release is not made, and has not been approved, by an “authorised person” within the meaning of Article 21(1) of the Financial Services and Markets Act 2000. As a consequence, this press release is directed only at persons who (i) are located outside the United Kingdom, (ii) have professional experience in matters relating to investments and fall within Article 19(5) (“investment professionals”) of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005, (iii) are persons falling within Article 49(2)(a) to (d) (“high net worth companies, unincorporated associations, etc.”) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 or (iv) are persons to whom this communication may otherwise lawfully be communicated (all such persons together being referred to as “Relevant Persons”). The Notes are directed only at Relevant Persons and no invitation, offer or agreements to subscribe, purchase or otherwise acquire Notes may be proposed or made other than with Relevant Persons. Any person other than a Relevant Person may not act or rely on this document or any provision thereof. This press release is not a prospectus which has been approved by the Financial Services Authority or any other United Kingdom regulatory authority for the purposes of Section 85 of the Financial Services and Markets Act 2000.

Some of the information contained in this announcement may contain forward-looking statements including statements pertaining to the timing and price range of the offering and the first day of trading.  These statements are based on current expectations that involve a number of risks and uncertainties which could cause actual results to differ from those anticipated.  A number of factors could cause actual results or events to differ materially from those express or implied by forward-looking statements, including without limitation: conditions in the markets; the financial position, cash flows and liquidity of the Company; changing business or other market conditions; and general economic conditions.  These and other factors could adversely affect the outcome and financial effects of the plans and events described in this announcement.  The Company does not intend to update these statements to reflect events and circumstances occurring after the date hereof or to reflect the occurrence of unanticipated events.